RecruitingPhase 3NCT06660992

A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-cystic Fibrosis Bronchiectasis

Sponsor

Haisco Pharmaceutical Group Co., Ltd.

Enrollment

669 participants

Start Date

Sep 30, 2024

Study Type

INTERVENTIONAL

Conditions

Non-cystic Fibrosis Bronchiectasis

Summary

This is a phase III, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HSK31858, tablet and a drug called Placebo for people with non-cystic fibrosis bronchiectasis. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHSK31858, tablet

HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis

DRUGPlacebo

the placebo comparator of study

Locations(2)

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Yixing People's Hospital

Yixingcun, Jiangxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06660992

Related Trials

A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

NCT0724540738 locations

A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

NCT075474363 locations

Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

NCT0648727357 locations

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

NCT066032467 locations

A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

NCT076163751 location